FDA guidance
Best Practices for Communication Between IND Sponsors and FDA During Drug Development
FDA guidance · Final · issued Dec 29, 2017
Key facts
| Title | Best Practices for Communication Between IND Sponsors and FDA During Drug Development |
|---|---|
| Status | Final |
| Issue date | Dec 29, 2017 |
| Center | Center for Drug Evaluation and Research |
| Issuing office | Center for Drug Evaluation and Research |
| Communication type | Good Review Practices |
| Regulated product | Drugs |
| Docket number | FDA-2017-D-6564 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents